Opinion

Podcast

Exploring Oral Systemic Therapies for Plaque Psoriasis: Efficacy, Safety, and Clinical Considerations

Author(s):

Lauren Miller, MPAS, PA-C,Jayme M Heim, MSN, FNP-BC

Lauren Miller, MPAS, PA-C; Jayme M. Heim, MSN FNP-BC, and Kirk Gautier, PA-C, discuss recent advancements in plaque psoriasis treatment, focusing on novel oral systemic therapies like the TYK-2 inhibitor deucravacitinib and its clinical trial data, to inform therapeutic decisions for this systemic disease.

Related Videos
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Virginia Clark, MD | Credit: University of Florida Health
Discussing FDA Approval of Tapinarof Cream for Atopic Dermatitis, with John Browning, MD
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Related Content
Phase 2 Data on ESO-101 Suggests Efficacy Among Adults with Eosinophilic Esophagitis
December 17th 2024

Phase 2 Data on ESO-101 Suggests Efficacy Among Adults with Eosinophilic Esophagitis

Tim Smith
Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor
December 16th 2024

Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
FDA logo black and white | Credit: US Food and Drug Administration
December 17th 2024

FDA Adds Boxed Warning to Fezolinetant (Veozah) for Liver Injury Risk

Abigail Brooks, MA
Irl Hirsch, MD | Credit: University of Washington
December 12th 2024

Diabetes Dialogue: Celebrating 25 Years of CGM, with Irl Hirsch, MD

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Houman Ashrafian, MD, PhD | Credit: Sanofi
December 17th 2024

Duvakitug Meets Primary Endpoints in Phase 2b RELIEVE UCCD Study for IBD

Abigail Brooks, MA
2024’s Needle-Free Approvals Transform Management of Anaphylaxis, Influenza in Children
December 17th 2024

2024’s Needle-Free Approvals Transform Management of Anaphylaxis, Influenza in Children

Joshua Fitch
© 2024 MJH Life Sciences

All rights reserved.